Application of immunotherapy in relapsed/refractory B-cell acute lymphoblastic leukemia
- VernacularTitle:免疫治疗在复发/难治性急性B淋巴细胞白血病中的应用
- Author:
Qihui CHU
1
;
Tong GAO
2
;
Suxin QU
1
;
Meixing YAN
1
Author Information
1. Dept. of Pharmacy，Qingdao Women and Children’s Hospital，Qingdao University，Shandong Qingdao 266034，China
2. Dept. of Pharmacy，the Affiliated Hospital of Qingdao University，Shandong Qingdao 266003，China
- Publication Type:Journal Article
- Keywords:
relapsed/refractory B-cell acute lymphoblastic leukemia;
immunotherapy;
CAR-T therapy;
monoclonal antibodies
- From:
China Pharmacy
2024;35(7):886-889
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy， as an emerging treatment method， has been proven to improve the prognosis of patients with relapsed/refractory B-cell acute lymphoblastic leukemia （B-ALL） and has good application prospects. Immunotherapy， including chimeric antigen receptor T cell immunotherapy （CAR-T） and monoclonal antibodies， has shown great potential for application， and has been approved for marketing. This article summarizes the application of the above two therapies in the treatment of relapsed/ refractory B-ALL， and concludes that CAR-T is a kind of personalized immunotherapy， and the selection of ideal targets is an important part of its action. Currently， the ideal targets in clinical studies include CD19， CD22 and CD19/CD22. Monoclonal antibodies， including blinatumomab and inotuzumab ozogamicin， have shown superior therapeutic efficacy for relapsed/refractory B- ALL. Immunotherapy has shown superior therapeutic effects compared to conventional chemotherapy， expanding the selection of treatment options for relapsed/refractory B-ALL.
